Abstract
Objective To use meta-analysis to systematically compare the efficacy and adverse reaction rates of albumin paclitaxel and docetaxel in the treatment of breast cancer. Methods This study included Chinese and English literature studies on clinical controlled studies of albumin paclitaxel and docetaxel in the treatment of breast cancer by searching CNKI, Weipu, Wanfang, PubMed, Embase, and Cochrane Library. Two researchers participated in the screening of the literature, used the inclusion and exclusion criteria as reference indicators, extracted relevant data, and used the software RevMan5.3 to conduct quality evaluation and meta-analysis of the literature. Results 4 literature stuides were retrieved that met the inclusion criteria, with 243 study subjects. The included literature had a lower risk of bias. Meta-analysis results showed that compared with the docetaxel group, the protein paclitaxel group had significant differences in objective effective rate (ORR) (OR = 1.56, 95% CI (0.80, 3.03), P=0.19), complete remission (CR) (OR = 1.79, 95% CI (0.96, 3.35), P=0.07), partial remission (PR) (OR = 0.88, 95% CI (0.53, 1.47), P=0.62), nausea (OR = 0.87, 95% CI (0.51, 1.74), P=0.84), and vomiting (OR = 0.62, 95% CI (0.45, 1.78) P=0.76). The reason may be that the number of literatures included in this study is small or the sample size is insufficient. However, it had an advantage in the incidence of neutropenia (OR = 0.38, 95% CI (0.16, 0.88), P=0.02), and the difference between the two groups was statistically significant. Conclusion Albumin paclitaxel treatment can better reduce the incidence of neutropenia in breast cancer patients and is of great significance to the safety of breast cancer patients.
Highlights
Breast cancer is a highly heterogeneous disease. e main reason for its occurrence is the mutation of HER2, BRCA1, BRCA2, RB, and other genes in patients due to factors such as heredity, environment, age, lifestyle, and diet
We searched a total of 486 articles, and after the first round of screening, we screened out the repeated articles in various databases
We screen out 145 articles, and we screen out 283 articles, including those that have no obvious relationship with the research content and without a complete article. e types of articles are review and case reports. en, we read all the articles in a deeper level and deleted a total of 54 articles, including those with incomplete experimental data
Summary
Breast cancer is a highly heterogeneous disease. e main reason for its occurrence is the mutation of HER2, BRCA1, BRCA2, RB, and other genes in patients due to factors such as heredity, environment, age, lifestyle, and diet. Paclitaxel is a broad-spectrum anticancer drug extracted from Taxus brevifolia and has shown good clinical efficacy in breast cancer tumors [1]. Docetaxel is a cytotoxic taxane compound obtained by semisynthesis of noncytotoxic precursor compounds extracted from European yew [3]. It has good anticancer activity and is widely used chemotherapy for breast cancer. Albumin paclitaxel and docetaxel are widely used in the treatment of breast cancer, but few people have compared their efficacy and safety in the treatment of breast cancer. A comprehensive and systematic comparison of the clinical efficacy and safety of albumin paclitaxel and docetaxel in the treatment of breast cancer provides ideas for the treatment of breast cancer of paclitaxel drugs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
